6,675 Quell ® Devices Shipped, Up 48% Compared to Q3 2015 DPNCheck ® Shipments at All-Time High of 54,300 Biosensors Revenue Up 94% to $2.7 Million Compared to Q4 2014 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the full

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it plans to issue its 2015 full year and fourth quarter financial results before the opening of the market on January 28, 2016 . The Company will host a conference call at 8:00 a.m., Eastern Time on January

The Only FDA Cleared Wearable Device for 24/7 Chronic Pain Relief Without a Prescription WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be exhibited at NY16 - Podiatric Clinical Conference and Exhibition sponsored

Omron Healthcare Leads Local Initiatives WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported regulatory approval in China for DPNCheck ® , a diagnostic test for peripheral neuropathy. DPNCheck is now registered as a Class II Medical Device under the Regulations for

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced a high level of interest in Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable at CES 2016. Highlights of the Week include: Quell was selected as one of 10 finalists in the CES Last Gadget

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported preliminary

To be Available in March 2016 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it received a 510(k) clearance (K152954) from the U.S. Food and Drug Administration (FDA) for an upgraded version of Quell, the company's over-the-counter, 100% drug free chronic

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA. Dr. Gozani intends to provide an overall business update and a

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin , Senior Vice President and General Manager, Consumer will participate in a panel titled "Wearables: Sleeker Smarter Faster" on Thursday, January 7 at 4:30pm (Pacific) at the 2016 CES Event in Las

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 13,800 shares of Series C convertible preferred stock at a